Neurotransmitters and electroconvulsive therapy

Journal of ECT

Volumn 30, Issue 2, 2014, Pages 116-121

  Baldinger, Pia ^a   Lotan, Amit ^b   Frey, Richard ^a   Kasper, Siegfried ^a   Lerer, Bernard ^b   Lanzenberger, Rupert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antidepressant; Dopamine; Electroconvulsive therapy; Neurotransmitters; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; FENFLURAMINE; FLUORODEOXYGLUCOSE F 18; HOMOVANILLIC ACID; NEUROTRANSMITTER; PROLACTIN; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SETOPERONE; SETOPERONE F 18; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE; SEROTONIN;

ANTERIOR CINGULATE; DENTATE GYRUS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; ELECTRIC SHOCK; ELECTROCONVULSIVE THERAPY; ELECTROPHYSIOLOGY; FRONTAL CORTEX; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; GENETIC ASSOCIATION; HAMILTON SCALE; HIPPOCAMPUS; HUMAN; LIMBIC CORTEX; MAJOR DEPRESSION; MICRODIALYSIS; MOTOR RETARDATION; NONHUMAN; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SENSITIZATION; SEROTONIN RELEASE; SEROTONIN UPTAKE; SEROTONINERGIC TRANSMISSION; SPECIES DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TURNOVER TIME; ANIMAL; METABOLISM; PHYSIOLOGY; PROCEDURES; SEIZURES;

ANIMALS; DOPAMINE; ELECTROCONVULSIVE THERAPY; HUMANS; NEUROTRANSMITTER AGENTS; SEIZURES; SEROTONIN;

EID: 84901592664     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000138     Document Type: Review

References (62)

1. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders; Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334-385.
2. Nobler M, Sackeim H. Electroconvulsive therapy. In: Helmchen H, Henn F, Lauter H, Sartorius N, eds. Contemporary Psychiatry. Vol. 3. Berlin, Germany: Springer; 2000: 425-434.
3. Frey R, Schreinzer D, Heiden A, et al. [Use of electroconvulsive therapy in psychiatry]. Nervenarzt. 2001;72:661-676.
4. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839-846. (Pubitemid 23084338)
5. Fink M. Convulsive therapy: A review of the first 55 years. J Affect Disord. 2001;63:1-15. (Pubitemid 32200493)
6. Eitan R, Lerer B. Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci. 2006;8:241-258. (Pubitemid 44113994)
7. Newman ME, Gur E, Shapira B, et al. Neurochemical mechanisms of action of ECS: evidence from in vivo studies. J ECT. 1998;14:153-171. (Pubitemid 28433912)
8. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425-434. (Pubitemid 30257256)
9. Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatr Clin North Am. 1991;14:905-923.
10. Ishihara K, Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol. 1999;80:185-189. (Pubitemid 29381085)
11. Goodwin GM, De Souza RJ, Green AR. Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berl). 1987;91:500-505. (Pubitemid 17038216)
12. Dremencov E, Gur E, Lerer B, et al. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:729-739. (Pubitemid 36966753)
13. deMontigny C. Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin. J Pharmacol Exp Ther. 1984;228:230-234.
14. de Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science. 1978;202:1303-1306. (Pubitemid 9116089)
15. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15:220-226. (Pubitemid 24210726)
16. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 1991;5:219-229.
17. Burnet PW, Sharp T, LeCorre SM, et al. Expression of 5-HT receptors and the 5-HT transporter in rat brain after electroconvulsive shock. Neurosci Lett. 1999;277:79-82.
18. BurnetPW,MeadA, Eastwood SL, et al. Repeated ECS differentially affects rat brain 5-HT1A and 5-HT2A receptor expression. Neuroreport. 1995;6:901-904.
19. Vetulani J, Lebrecht U, Pilc A. Enhancement of responsiveness of the central serotonergic system and serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. Eur J Pharmacol. 1981;76:81-85. (Pubitemid 12252175)
20. Green AR, Johnson P, Nimgaonkar VL. Increased 5-HT2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine- mediated behaviour following repeated electroconvulsive shock administration to rats. Br J Pharmacol. 1983;80:173-177. (Pubitemid 13000893)
21. Strome EM, Clark CM, Zis AP, et al. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: An in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry. 2005;57:1004-1010. (Pubitemid 40603083)
22. Attar-Levy D, Martinot L, Blin J, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry. 1999;45:180-186. (Pubitemid 29079448)
23. Yatham LN, Liddle PF, Dennie J, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry. 1999;56:705-711. (Pubitemid 29357731)
24. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001;158:78-85. (Pubitemid 32047250)
25. Mischoulon D, Dougherty DD, Bottonari KA, et al. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Res. 2002;116:151-161. (Pubitemid 35441319)
26. Gleiter CH, Nutt DJ. Repeated electroconvulsive shock does not change [3H]-paroxetine binding to the 5-HT uptake site in rat cortical membranes. Psychopharmacology (Berl). 1988;95:68-70.
27. Hayakawa H, Okamoto Y, Shimizu M, et al. Single or repeated treatment with electroconvulsive shock increases number of serotonin uptake binding sites in the frontal cortex. Neuropsychobiology. 1995;31:1-5.
28. Shen H, Numachi Y, Yoshida S, et al. Electroconvulsive shock increases serotonin transporter in the rat frontal cortex. Neurosci Lett. 2003;341:170-172. (Pubitemid 36401595)
29. Saijo T, Takano A, Suhara T, et al. Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: A PET study with [11C]WAY 100635. Int J Neuropsychopharmacol. 2010;13:785-791.
30. Gur E, Lerer B, Newman ME. Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: An in vivo microdialysis study. J Neural Transm. 1997;104:795-804. (Pubitemid 27507327)
31. Stockmeier CA, Wingenfeld P, Gudelsky GA. Effects of repeated electroconvulsive shock on serotonin1A receptor binding and receptor-mediated hypothermia in the rat. Neuropharmacology. 1992;31:1089-1094.
32. Lanzenberger R, Baldinger P, Hahn A, et al. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry. 2013;18:93-100.
33. Spindelegger C, Lanzenberger R, Wadsak W, et al. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry. 2008;14:1040-1050.
34. Shapira B, Lerer B, Kindler S, et al. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. Br J Psychiatry. 1992;160:223-229.
35. Yatham LN, Liddle PF, Lam RW, et al. Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry. 2010;196:474-479.
36. Kellar KJ, Cascio CS, Butler JA, et al. Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain. Eur J Pharmacol. 1981;69:515-518. (Pubitemid 11137162)
37. Nomikos GG, Zis AP, Damsma G, et al. Electroconvulsive shock produces large increases in interstitial concentrations of dopamine in the rat striatum: An in vivo microdialysis study. Neuropsychopharmacology. 1991;4:65-69.
38. Zis AP, Nomikos GG, Damsma G, et al. In vivo neurochemical effects of electroconvulsive shock studied by microdialysis in the rat striatum. Psychopharmacology (Berl). 1991;103:343-350.
39. McGarvey KA, Zis AP, Brown EE, et al. ECS-induced dopamine release: Effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry. 1993;34:152-157. (Pubitemid 23257741)
40. Stenfors C, Bjellerup P, Mathé AA, et al. Concurrent analysis of neuropeptides and biogenic amines in brain tissue of rats treated with electroconvulsive stimuli. Brain Res. 1995;698:39-45.
41. Strome EM, Zis AP, Doudet DJ. Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci. 2007;32:193-202. (Pubitemid 46903860)
42. Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5:378-388. (Pubitemid 30455951)
43. West CHK, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. Int J Neuropsychopharmacol. 2011;14:201-210.
44. Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: electrophysiological studies in the rat brain. Synapse. 2013;67:716-727.
45. Landau AM, Chakravarty MM, Clark CM, et al. Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology. 2011;36:511-518.
46. Nomikos GG, Mathe AA, Mathe JM, et al. MK-801 prevents the enhanced behavioural response to apomorphine elicited by repeated electroconvulsive treatment in mice. Psychopharmacology (Berl). 1992;108:367-370.
47. Smith SE, Sharp T. Evidence that the enhancement of dopamine function by repeated electroconvulsive shock requires concomitant activation of D1-like and D2-like dopamine receptors. Psychopharmacology. 1997;133:77-84. (Pubitemid 27395823)
48. Nikisch G, Mathé AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry. 2008;23:356-359.
49. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1185-1190.
50. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off " phenomena. Acta Neurol Scand. 1987;76:191-199. (Pubitemid 17144130)
51. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord. 1991;6:293-303.
52. Henry ME, Schmidt ME, Matochik JA, et al. The effects of ECT on brain glucose: A pilot FDG PET study. J ECT. 2001;17:33-40. (Pubitemid 32246863)
53. Costain DW, Cowen PJ, Gelder MG, et al. Electroconvulsive therapy and the brain: evidence for increased dopamine-mediated responses. Lancet. 1982;2:400-404. (Pubitemid 12039834)
54. Saijo T, Takano A, Suhara T, et al. Electroconvulsive therapy decreases dopamine D2receptor binding in the anterior cingulate in patients with depression: A controlled study using positron emission tomography with radioligand [11C]FLB 457. J Clin Psychiatry. 2010;71:793-799.
55. Huuhka K, Anttila S, Huuhka M, et al. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neurosci Lett. 2008;448:79-83.
56. Dannlowski U, Domschke K, Birosova E, et al. Dopamine D3 receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. Int J Neuropsychopharmacol. 2013;16:1443-1459.
57. Fosse R, Read J. Electroconvulsive treatment: hypotheses about mechanisms of action. Front Psychiatry. 2013;4.
58. Pruessner JC, Champagne F, Meaney MJ, et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C] raclopride. J Neurosci. 2004;24:2825-2831. (Pubitemid 38380960)
59. Tononi G, Koch C. The neural correlates of consciousness: An update. Ann N Y Acad Sci. 2008;1124:239-261. (Pubitemid 351506781)
60. Palmiter RD. Dopamine signaling as a neural correlate of consciousness. Neuroscience. 2011;198:213-220.
61. Schlaepfer TE, Cohen MX, Frick C, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33:368-377. (Pubitemid 350243349)
62. Savli M, Bauer A, Mitterhauser M, et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage. 2012;63:447-459.